Improved radiographic progression-free survival (rPFS) regardless of disease volume or metastatic presentation achieved with ...

Detailed results from pivotal TALAPRO-3 study presented at ASCO 2026 and published in The New England Journal of Medicine TALZENNA plus XTANDI demonstrated a 52% reduction in the risk of radiographic ...

A previous trial involving patients with metastatic prostate cancer that was resistant to androgen pathway modulation (formerly referred to as castration-resistant) showed that adding talazoparib ...

ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate Cancer ...

*Foster Sylvers, the former child star whose youthful voice and magnetic stage presence helped propel The Sylvers to national fame in the 1970s, has died. He was 64. His brother, Leon Sylvers III, ...

Olema’s novel KAT6 inhibitor, in combination with darolutamide in approximately 36 patients; expected to initiate in ...

Bayer Shares New Findings for NUBEQA for Cognitive Decline in Men with aPC Compared to Enzalutamide in Phase II ARACOG Head-to-Head Trial ...

Pfizer appears to have one-upped Johnson & Johnson again in their PARP inhibitor battle in prostate cancer. After winning a broader FDA label in metastatic castration-resistant prostate cancer (mCRPC) ...

More durable, deeper PSA response in patients treated with Pluvicto plus standard of care (ARPI + ADT) vs. SoC aloneDeep PSA ...

The ArteraAI Prostate Test (mHSPC) is the first externally developed digital pathology algorithm being made clinically available through the Tempus ecosystem. This AI-powered test assesses a patient's ...

GLP-1 receptor agonists may help mitigate progression of at least some obesity-related cancers, according to retrospective ...